GlassScriptPhysician profile
Kelvin S Panesar
NPI 1942281654
$9,269.33
in general payments reported to CMS, 2019-2025
29 companies · $564 in 2025
The $564 reported for 2025 was more than what 80% of Pediatric Pulmonology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,937 · 2020: $1,011 · 2021: $1,825 · 2022: $1,728 · 2023: $1,275 · 2024: $931 · 2025: $564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,614 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,613.58 |
| Education | $155.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $2,032.41 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Chiesi USA, INC. | $946.34 | 2019-2023 | Bronchitol |
| Regeneron Healthcare Solutions, INC. | $684.44 | 2019-2025 | Dupixent |
| Vertex Pharmaceuticals Incorporated | $677.09 | 2019-2024 | Trikafta |
| Baxter Healthcare | $669.97 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Volara System |
| Astrazeneca Pharmaceuticals LP | $602.29 | 2019-2022 | |
| Abbvie INC. | $530.88 | 2019-2025 | |
| Advanced Respiratory, INC | $508.74 | 2019-2021 | |
| Digestive Care, INC. | $455.15 | 2023-2025 | Pertzye |
| Genentech USA, INC. | $298.47 | 2021-2024 | Xolair |
| Gilead Sciences, INC. | $253.14 | 2019-2022 | |
| Kaleo, INC. | $202.11 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $186.75 | 2021-2023 | |
| Glaxosmithkline, LLC. | $143.86 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $128.09 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $125.08 | 2019-2025 | |
| Grifols USA, LLC | $112.06 | 2020-2022 | |
| Covis Pharma Gmbh | $106.66 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.05 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $80.95 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $77.89 | 2024-2025 | Zenpep |
| Inspire Medical Systems, INC. | $70.31 | 2023-2024 | Inspire |
| Sobi, INC | $69.16 | 2022-2023 | |
| Sanofi Pasteur INC. | $51.86 | 2025 | |
| Electromed, INC. | $47.05 | 2021 | |
| Allergan, INC. | $43.71 | 2019 | |
| Breas Medical, INC. | $39.40 | 2023-2024 | Vivo 45 Ls |
| Mylan Specialty L.P. | $22.24 | 2021 | |
| Ucb, INC. | $17.18 | 2025 | Nayzilam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelvin Panesar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.